|
|
||||||||
1 Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA
2 Department of Neurology, University of California, San Francisco, California 94143, USA
3 Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
4 Department of Medicine, University of California, San Francisco, California 94143, USA
5 Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA
6 Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143, USA
Reprint requests to: Stanley B. Prusiner, Institute for Neurodegenerative Diseases, Box 0518, University of California, San Francisco, CA 94143-0518; e-mail: hang{at}itsa.ucsf.edu; fax: (415) 476-8386.
(RECEIVED September 19, 2000; FINAL REVISION January 23, 2001; ACCEPTED January 23, 2001)
Article and publication are at www.proteinscience.org/cgi/doi/10.1110/ps.39201
| Abstract |
|---|
|
|
|---|
75-d incubation periods; a concentration of 1.08 M was found for the DY strain with a
170-d incubation period and
1.25 M for the SHa(RML) and 139H isolates with
180-d incubation periods. A mean value of 1.39 M GdnHCl for the Me7-H strain with a
320-d incubation period was found. Based on these results, the eight prion strains segregated into four distinct groups. Our results support the unorthodox proposal that distinct PrPSc conformers encipher the biological properties of prion strains. Keywords: Prion strains; spongiform encephalopathies; protein conformation; scrapie; prion protein; neurodegenerative disease
| Introduction |
|---|
|
|
|---|
-helical structure and essentially devoid of ß-sheet content. In contrast, PrPSc is insoluble in such detergents, is resistant to proteolysis except for the N-terminal region comprising
67 residues, and has a high ß-sheet content (Caughey et al. 1991; Gasset et al. 1993; Pan et al. 1993; Pergami et al. 1996; Safar et al. 1993). The protease-resistant fragment of PrPSc has a molecular size of 2730 kD and is designated PrP 2730 (Prusiner et al. 1983). It consists of
142 amino acids and conveys prion infectivity. In the presence of detergent, PrP 2730 readily polymerizes into amyloid although amyloid is neither obligatory for prion infectivity nor disease pathogenesis (Prusiner et al. 1983, 1990; McKinley et al. 1991). Protein denaturants abolish prion infectivity and protease resistance while increasing solubility and immunodetection of PrPSc (Kitamoto et al. 1987; Serban et al. 1990; Taraboulos et al. 1992; Prusiner et al. 1993; Oesch et al. 1994; Peretz et al. 1997; Safar et al. 1998). Thus, considerable evidence shows that prion diseases are disorders of protein conformation. Prion strains have been shown to breed true on repeated passage in animals of the same species as by phenotypic characteristics including the clinical presentation of disease (Pattison and Millson 1961; Mastrianni et al. 1999), the length of the incubation period (Dickinson et al. 1968), the distribution of vacuolar degeneration (Fraser and Dickinson, 1968; Fraser 1979), and the pattern of PrPSc deposition in the CNS (Bruce et al. 1989; Hecker et al. 1992). The phenomenon of prion strains has been cited frequently as evidence that an independently replicating informational molecule or genome exists within the infectious particle (Bruce and Dickinson 1987). To accommodate multiple strains in the absence of a nucleic acid, PrPSc must be able to sustain separate information states within the same amino acid sequence, and PrPC must be able to faithfully acquire this information during its conversion into PrPSc. Substantial evidence suggests that a direct interaction between PrPC and PrPSc leads to the conversion of PrPC to PrPSc (Prusiner et al. 1990; Horiuchi et al. 1999). Accordingly, different strains must maintain different templates of PrPSc structures, and these differences at the molecular level ultimately should dictate strain properties.
Persuasive evidence that strain-specific information is enciphered in the structure of PrPSc arose from the transmission of two different inherited human prion diseases to mice expressing a chimeric human/mouse (MHu2M) PrP transgene (Telling et al. 1996). In fatal familial insomnia (FFI), the protease-resistant fragment of PrPSc after enzymatic removal of the two N-linked glycans is 19 kD, whereas that from familial Creutzfeldt-Jacob disease (CJD) and sporadic CJD is 21 kD (Monari et al. 1994; Parchi et al. 1996). Extracts from the brains of patients with FFI transmitted disease to Tg mice and induced formation of the 19-kD PrPSc fragment; in contrast, extracts from the brains of patients with CJD produced the 21-kD PrPSc fragment in the same mice (Telling et al. 1996). These results showed that MHu2M PrPSc can exist in two different conformations based on the sizes of the protease-resistant fragments, yet, the amino acid sequence of MHu2M PrPSc remained invariant.
Although early comparisons of hamster prion strains did not reveal any particularly compelling biochemical differences in PrPSc (Kascsak et al. 1986; Hecker 1992), such differences were found for two transmissible mink encephalopathy (TME) prion strains, drowsy (DY) and hyper (HY), that were transmitted to hamsters (Bessen and Marsh 1992b). The DY strain was found to differ significantly from other known hamster prion strains in its biochemical and physical properties. Marked differences were identified by sedimentation analysis, protease sensitivity, and by the migration pattern of PrPSc proteolytic fragments on SDS gels (Bessen and Marsh 1992b). PrPSc comprising the DY prions showed diminished resistance to proteinase K digestion and yielded a protease-resistant fragment of 19 kD after deglycosylation, whereas that from HY was 21 kD (Bessen and Marsh 1994). Notably, TME strain properties could be preserved after transmission of either the full-length or the protease-resistant fragment of PrPSc, contending that strain characteristics are propagated by the protease-resistant core (Bessen and Marsh 1994).
Because most prion strains encipher PrPSc conformers that generally yield PrP 2730 with a polypeptide core of 21 kD after limited proteolysis, it has not been possible to use the mobility-shift assay to detect plausible differences in PrPSc conformation in most cases (Bessen and Marsh 1994; Monari et al. 1994; Parchi et al. 1996; Telling et al. 1996; Scott et al. 1997). Moreover, the insolubility of PrPSc has prevented comparative structural studies of prion strains by using high-resolution nuclear magnetic resonance and X-ray diffraction techniques. Of note, Fourier-transform infrared spectroscopy of the HY and DY strains did give different spectra (Caughey et al. 1998). A conformation-dependent immunoassay (CDI) was used to investigate the eight SHa prion isolates studied here by quantification of the immunoreactivity of denatured (D) and native (N) PrPSc (Safar et al. 1998). The monoclonal antibody (mAb) 3F4 used in those studies recognizes a conformationally sensitive epitope (Peretz et al. 1997). In a plot of the D/N ratio as function of PrPSc concentration, each isolate occupied a unique position, a result consistent with the existence of multiple discrete PrPSc conformers that are strain-specified (Safar et al. 1998).
To test the hypothesis that the biological properties of prion strains are enciphered in the conformation of PrPSc, we examined the relative conformational stability of PrPSc derived from the SHa brains infected with eight strains. Because PrP 2730, the protease-resistant core of PrPSc, is infectious and can initiate the faithful propagation of strains (Prusiner et al. 1983; Bessen and Marsh 1994), we studied the conformational stability of this molecule. Using sensitivity to protease as a marker for the denatured state of PrP 2730, we characterized the protein conformations of eight hamster prion isolates. We found that these eight strains could separate into four groups based on relative conformational stability and incubation period. The sigmoidal shape of the conformational transition curves shows that the unfolding of PrPSc from a protease-resistant state to a sensitive one is a cooperative process. Our findings support the proposition that PrPSc can adopt multiple conformations. By inference, these results lend additional support to the hypothesis that the conformation of PrPSc enciphers the biological properties of prion strains.
| Results |
|---|
|
|
|---|
Guanidine hydrochloride denaturation of PrP 2730
To extend the comparative analysis of the Sc237 and DY strains, we prepared a crude brain fraction by differential centrifugation and detergent extraction previously designated P2 (Prusiner et al. 1984). Aliquots of the P2 fraction were incubated with increasing concentrations of guanidine hydrochloride (GdnHCl) for 1 h followed by dilution of the GdnHCl and limited proteolysis (Fig. 1
). By Western blotting using the 3F4 fragment antibody (Fab), the amount of PrP 2730 for the Sc237 and DY strains remained unchanged up to 0.8 M GdnHCl. Exposure to 1.0 M GdnHCl did not alter the extent of digestion of PrP 2730 of the Sc237 strain but caused a dramatic increase in the susceptibility to protease of PrP 2720 of the DY strain. At higher concentrations of GdnHCl, the PrP 2730 of the DY strain disappeared, and that of the Sc237 strain gradually diminished. Reductions in the amounts of PrP 2730 from both strains were not followed by the appearance of protease degradation products, suggesting that once a PrPSc is rendered protease sensitive by GdnHCl, the entire protein is rapidly degraded. Moreover, we could find no evidence to suggest that degradation of PrP 2730 of the Sc237 strain proceeded along a pathway in which PrP 2730 of the DY strain was an intermediate. When the same study was repeated with the N-terminal D13 Fab and the C-terminal R1 Fab, similar patterns of PrP 2730 stability for the Sc237 and DY strains were found (data not shown).
|
|
1.0 M GdnHCl, whereas for the DY strain, it was constant up to
0.6 M. Once the levels of PrP 2730 began to decrease, the diminution was progressive and approached zero at a concentration of
2.0 M GdnHCl for Sc237 and
1.5 M for DY.
The most reliable interpolation of values for such sigmoidal curves occurs in the middle portion between the two asymptotes, that is, the inflection point, of the curve rather than farther along the asymptotes (Rodgers 1984). Therefore, we used the GdnHCl concentration found at the half-maximal denaturation (GdnHCl1/2) as a measure of the relative conformational stability of PrPSc. Consistently, we found that coating the ELISA plates with 25 µg/mL of protein results in lower signals compared with those obtained with 12.5 µg/mL protein (Fig. 2B,C
). That coating with high protein concentrations leads to reductions in final signals is well documented, and at least two different mechanisms have been suggested to explain this phenomenon (Cantarero et al. 1980). Therefore, measurements of GdnHCl1/2 values were obtained from ELISA plates coated with 10 µg/mL of protein. At these protein concentrations, the mean GdnHCl1/2 values for PrP 2730 of the DY and Sc237 strains were 1.08 M and 1.47 M, respectively (Table 1
).
|
1.0 M for the HY, SHa(ME7), and MT-C5 strains. The GdnHCl1/2 values for these four strains ranged from 1.47 M to 1.5 M and were not statistically different from each other. In contrast, treatment of the 139H and SHa(RML) strains with 1.0 M GdnHCl resulted in denaturation of
25% of the PrP 2730. The GdnHCl1/2 values for the SHa(RML) and 139H strains were 1.25 M and 1.26 M GdnHCl, respectively. The GdnHCl1/2 value for the ME7-H strain was 1.39 M GdnHCl.
|
The similar GdnHCl1/2 values observed for PrP 2730 molecules of the four strains Sc237, HY, SHa(ME7), and MT-C5 are notable; moreover, these four strains display incubation periods of
75 days (Fig. 4
; Table 1
). Interestingly, the GdnHCl1/2 values found for the 139H and SHa(RML) strains were similar, and both these strains have incubation times of
180 days. In contrast, the DY strain, with an incubation time similar to that of the 139H and SHa(RML) strains, has a strikingly different GdnHCl1/2 value. It is noteworthy that size of the deglycosylated PrP 2730 polypeptide is 19 kD for the DY strain and 21 kD for the 139H and SHa(RML) strains as well as the other five strains analyzed in this study. The Me7-H strain had an incubation time of
320 days and a GdnHCl1/2 value of 1.39 M, indicating that there is no quantitative relation between the length of the incubation period and the conformational stability of PrP 2730 (Fig. 4
). Notably, Me7-H, Sc237, and HY had GdnHCl1/2 values that were not significantly different at P < 0.05 (Table 1
), suggesting that relative conformational stability alone cannot always used to discriminate strains.
|
|
| Discussion |
|---|
|
|
|---|
The foregoing findings set the stage to ask how many conformations PrPSc can adopt. Before the finding that PrPC and PrPSc have the same covalent structure but possess different conformations, it generally was accepted that a particular amino acid sequence adopts only one biologically active conformation (Anfinsen 1973). To explore the range of biologically active conformations that PrPSc can adopt, we chose two different approaches. First, we developed the CDI, a new assay for PrPSc that does not require proteolytic digestion of PrPC before measuring PrPSc. The CDI not only measures the precursor of PrP 2730, which is denoted rPrPSc, but it also measures an intermediate in prion replication, denoted sPrPSc for a protease-sensitive form of PrPSc (Safar et al. 1998). The levels of both rPrPSc and sPrPSc were found to be specified by the prion strain, but only the level of sPrPSc showed a correlation with the strain-specified disease characteristic, that is, the level of sPrPSc was directly proportional to the length of the incubation time. Second, we developed a conformational stability assay for PrP 2730 that is more discriminating than limited proteolysis and migration on SDS-PAGE, as reported here.
Measurements of the conformational stability of soluble proteins have shown that slight differences in protein structure can be measured by exposure to a denaturant over an appropriate range of concentrations (Shirley 1995). These studies require the determining of the equilibrium constant and the free energy change,
G, for the reaction folded
unfolded. Because these are thermodynamic values, it is necessary that the unfolding reaction has reached equilibrium and that the unfolding reaction is reversible. Based on such findings, we developed a procedure in which PrPSc in crude fractions is exposed to GdnHCl and then digested with proteinase K. As the concentration of GdnHCl increased, the digestion of PrP 2730 increased concomitantly. However, in experiments involving insoluble oligomeric forms of PrPSc, denaturation reversibility is not attainable, and therefore we did not calculate the
G of PrPSc. Alternatively, we chose to use the GdnHCl concentration found at the half-maximal denaturation (GdnHCl1/2) as a measure for the relative conformational stability of PrPSc. As reported here, the procedure yielded highly reproducible curves that, with incubation time to disease, could discriminate four different groups of strains from the eight that were studied.
We found that each strain had a characteristic relative conformational stability and that, in some cases, differences in relative stability were of sufficient magnitude that strains could be clearly discriminated based on this criterion alone. For example, the GdnHCl1/2 value of the DY strain (
1.0 M) was markedly different from that of the HY strain (
1.5 M) and Me7-H (1.4 M) isolates. Similarly, the SHa(RML) and 139H strains, with GdnHCl1/2 values of
1.25 M, could be readily discriminated from DY (
1.0 M) although all three have similar incubation periods. It was also possible to distinguish the SHa(RML) and 139H strains from the SHa(Me7), Me7-H, HY, Sc237, and MT-C5 strains even though these strains could not be discriminated using the SDSgel mobility-shift assay (Scott et al. 1997). Thus, relative conformational stability may provide a useful biochemical marker for strain typing. To put this proposal in context, the recent demonstration that BSE could be experimentally transmitted to sheep has raised considerable concern in the United Kingdom that sheep exposed to contaminated animal feed might be harboring BSE (Foster et al. 1993). Perhaps a comparison of the relative conformational stability of sheep-passaged BSE and natural sheep scrapie prions might allow a simple diagnostic test suitable for screening the British sheep population for the presence of BSE to be designed.
Notably, we also found that some strains, previously known to be distinct by other criteria, such as Sc237 and Me7-H, had relative conformational stabilities that were similar (
1.5 M vs.
1.4 M GdnHCl). These results suggest that the criterion of relative conformational stability alone cannot always be used to discriminate strains. However, even in such instances, relative stability may be used to complement other phenotypic criteria when comparing prion strains. When the eight prion isolates were analyzed by the dual criteria of incubation period and relative conformational stability (Fig. 4
), it became clear that the eight strains could be segregated into only four clusters of strains.
No quantitative relation between the length of the incubation time and the degree of conformational stability could be discerned (Fig. 4
). Before this study, it was certainly a possibility that variations in incubation period seen with prion strains might be caused by variation in the stability of PrP 2730, but our new work clearly shows that this is not the case. We interpret these findings to suggest that strain characteristics, like rate of PrPSc formation as well as sites of replication and accumulation, ultimately might be more important in determining incubation time to disease. It is noteworthy that no relation between the level of PrP 2730 and the length of the incubation time could be found for these same eight strains using the CDI; however, the level of sPrPSc was directly proportional to the length of the incubation time (Safar et al. 1998). The conformational stability assays reported here cannot be compared directly with this finding because they have not been performed on sPrPSc.
Based on our conformational stability assays, it can be argued that Sc237, HY, SHa(ME7), and MT-C5 are a single strain of prion. They have the same incubation times in hamsters, and they show indistinguishable conformational stability curves (Table 1
; Fig. 3
). When the distribution of vacuolation and the pattern of PrPSc deposition in brains of Syrian hamsters inoculated with SHa(RML), SHa(Me7), Me7-H, and Sc237 strains were compared, only the Me7-H strain was markedly different by both criteria (Scott et al. 1997). Also, whereas SHa(RML), SHa(Me7), and Sc237, distinct from Me7-H, the SHa(RML) strain gave a pattern of deposition that could be discriminated easily by histoblotting from the SHa(Me7) and Sc237 strains, which showed only minor differences in the intensity and distribution of the PrPSc signal (Scott et al. 1997). Therefore, based on multiple criteria of incubation period, neuropathology, and PrPSc conformational stability, it certainly is possible that at least the SHa(Me7) and Sc237 strains represent a single strain of prion. However, note that both of these strains, together with HY and MT-C5, could be discriminated by CDI in plots of the concentration of PrPSc as a function of the D/N ratio (Safar et al. 1998). Whether these are truly four strains as can be argued from the CDI data or they are one strain based on incubation times and conformational stabilities remains to be established. The same questions attend to the SHa(RML) and 139H strains, with
180-d incubation periods and similar conformational stabilities.
The sigmoidal shape of the GdnHCl denaturation curves was similar for all eight strains examined (Figs. 2 and 3![]()
); furthermore, the shape of the curves was unaltered when a variety of recombinant Fabs directed against three different epitopes were used in addition to the 3F4 Fab (Table 2
). Additionally, the sigmoidal shape of the denaturation curves was independent of the concentration of protein used in the assay. These findings show that unfolding of PrP 2730 is a cooperative process.
Previously, a comparison of the reactivity of antibodies to PrPC with those to PrPSc dispersed in detergentlipidprotein complexes revealed that the major conformational differences between the two molecules lie within the N-terminal region of PrP 2730 corresponding to residues 90120 (Peretz et al. 1997). Whether this local conformational change alone can explain the protease resistance of residues 90231 comprising PrP 2730 or whether oligomerization plays an important role remains to be established. Results of ionizing radiation inactivation experiments show that the minimal infectious unit may be a dimer of PrPSc (Bellinger-Kawahara et al. 1988), suggesting that quaternary packing of PrPSc monomers might contribute to the structural change that confers the resistance of PrP 2730 residues to protease digestion.
Although we have chosen to interpret the conformational stability curves in terms of a two-state process, that is, the transition from the native to the denatured state, we recognize that the events that make up this transition are far more complicated. Under the conditions of our experiments at 0 M GdnHCl, it is likely that the digestion of rPrPSc produces PrP 2730 that rapidly polymerizes into rod-shaped structures with the properties of amyloid. As the concentration of GdnHCl is raised, it is unclear when the polymerization process ceases to occur. Whether polymerization of PrP 2730 into amyloid is more sensitive to disruption by GdnHCl than the events that render PrP 2730 susceptible to proteolysis is unknown.
The results presented here clearly show that PrPSc may adopt at least three different conformations. Each of these conformations is associated with a distinct disease phenotype suggesting that biological properties of each strain are enciphered in the tertiary and possibly quaternary structure of PrPSc. The mechanism by which prions replicate with a high degree of fidelity and thus are able to preserve the strain-specified properties is unknown. The existence of multiple prion strains (Table 1
; Fig. 4
) demands that the conformation of PrPSc be faithfully copied during prion replication. Some of us have suggested that such a process involves a template-assisted process in which one or more auxiliary molecules provisionally designated protein X facilitate the production of nascent PrPSc (Telling et al. 1995; Kaneko et al. 1997; Zulianello et al. 2000). An alternate proposal suggests that prion replication occurs through a nucleationpolymerization process (Gajdusek 1988; Jarrett and Lansbury 1993; Caughey and Chesebro 1997), but against this proposal is the finding that full-length PrPSc does not form regular polymers (McKinley et al. 1991) and prion replication is restricted to a few tissues although PrPC is much more widely expressed (Raeber et al. 1999). Only PrP 2730 and smaller fragments of PrP form regular polymers with the ultrastructural and tinctorial features of amyloid (Prusiner et al. 1983; Gasset et al. 1992; Forloni et al. 1993); moreover, amyloid polymers composed of PrP 2730 are clearly not obligatory for infectivity (Gabizon et al. 1987; McKinley et al. 1991; Wille et al. 1996). Elucidating the mechanism of PrPSc formation is likely to be important in defining the limits of prion diversity.
| Materials and methods |
|---|
|
|
|---|
Preparation of protein fraction P2
P2 fraction was prepared as previously described with slight modifications (Prusiner et al. 1984). Briefly, brains were homogenized (10% w/v) in 320 mM sucrose. The homogenate was centrifuged at 4000g for 30 min at 4°C. To the supernatant, we added Triton X-100 and DOC at detergent/protein (w/w) ratios of 4:1 and 2:1, respectively, and mixed for 1 h at 4°C. To the detergent extract, we added glycerol and polyethylene glycol (PEG) and mixed for 1 h at 4°C as described (Prusiner et al. 1984). The PEG precipitate was collected by centrifugation at 10,000g for 30 min at 4°C. The pellet, termed P2 (Prusiner et al. 1984), was resuspended in 20 mM Tris-acetate at pH 8.3 containing 0.02% Triton X-100 and 1 mM dithiothreitol and adjusted to a protein concentration of 10 mg/mL.
Expression and preparation of anti-PrP mouse Fabs
The preparation of Fabs libraries from PrP gene knockout mice (Prnp0/0) immunized with liposomes containing dispersed SHaPrP 2730 has been described (Peretz et al. 1997). Selected mouse Fab clones (i.e., D13, D18, and R2) were grown in quantity, and the Fabs were affinity-purified using polyclonal goat anti-mouse IgG Fab (Pierce) covalently bound to protein G matrix (Pharmacia) as described (Williamson et al. 1993). The 3F4 Fab fragments were prepared from hybridoma-derived 3F4 mAb (Kascsak et al. 1987) treated with the endopeptidase enzyme papain (Pierce).
Western blot analysis
An equal volume of 2 x sample buffer (Laemmli 1970) was added to protein samples. Each SDS-PAGE lane was loaded with 10 µg of total protein. PrP was detected with anti-PrP 3F4 monoclonal antibodies (1 µg/mL; Kascsak et al. 1987), and enhanced chemiluminescence detection method (Amersham Corporation).
ELISA denaturation transition
Aliquots of 25 µL from the P2 fraction (10 mg/mL) were mixed with 25 µL of GdnHCl stock solutions, with final GdnHCl concentrations ranging from 0 M to 4 M. GdnHCl stock solutions were prepared from an 8-M solution (Pierce) diluted in water. After 1 h of incubation at room temperature, all samples were diluted with phosphate-buffered saline to a final concentration of 0.1 M GdnHCl and 2% Sarkosyl in a volume of 1.5 mL. Proteinase K (PK) (0.5 µg) was added, and the samples were incubated for 1 h at 37°C. The reaction was stopped with 2 mM PMSF and a cocktail of protease inhibitors (Boehringer Mannheim). Proteins were precipitated with 4 volumes of methanol/chloroform (2:1 v/v) for 14 h at -20°C. Samples were centrifuged at 4000g for 30 min at 4°C. Pellets were resuspended in 50 µL of 6 M GdnSCN solution for 1 h and diluted into 1.5 mL of ELISA binding buffer (0.1 M bicarbonate at pH 8.6). ELISA wells were coated with 50 µL of solution containing 10 µg/mL of protein. To increase the immunoreactivity of PrPSc, we denatured coated proteins in situ with 50 µL of 6 M GdnSCN. After 10 min at room temperature, the plates were washed three times and blocked, and immunocomplexes of Fab-PrP were detected as described (Burton et al. 1991). PK was fully active in the presence of 0.1 M GdnHCl as measured by a colorimetric assay with carbobenzoxy-valyl-glycyl-arginine p-nitroanilide (Boehringer Mannheim).
Data analysis of ELISA denaturation transition curves
After addition of the color development substrate p-nitrophenyphosphate, ELISA plates were incubated for 1 h at 37°C, and color absorbance was measured at 405 nm by using spectrophotometer V-max (Molecular Devices). P2 samples prepared from normal SHa brains, proteinase K digested and methanol/chloroform precipitated, were used as blanks (O.D. value of
0.1). The O.D. patterns were best fitted using the four-parameter sigmoid equation (Maquard-Levendberg algorithm) using the software SigmaPlot (SPSS).
To plot the remaining fraction of PrPSc as a function of GdnHCl concentration, we expressed each measured O.D. (O.D.mean) within the curve as the apparent fractional extent of native PrPSc, given that at maximum fitted O.D. (O.D.max), all PrPSc is present, with a value of 1, and at O.D. close to zero (O.D.min), most of PrPSc is denatured and degraded by PK. The following equation was used (Kuwajima 1995):
.
| Acknowledgments |
|---|
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| References |
|---|
|
|
|---|
Bellinger-Kawahara, C.G., Kempner, E., Groth, D.F., Gabizon, R., and Prusiner, S.B. 1988. Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology 164: 537541.[CrossRef][Medline]
Bessen, R.A. and Marsh, R.F. 1992a. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J. Virol. 66: 20962101.
. 1992b. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J. Gen. Virol. 73: 329334.
. 1994. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68: 78597868.
Bruce, M.E. and Dickinson, A.G. 1987. Biological evidence that the scrapie agent has an independent genome. J. Gen. Virol. 68: 7989.
Bruce, M.E., McBride, P.A., and Farquhar, C.F. 1989. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci. Lett. 102: 16.[CrossRef][Medline]
Burton, D.R., Barbas, III, C.F., Persson, M.A., Koenig, S., Chanock, R.M., and Lerner, R.A. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. 88: 1013410137.
Cantarero, L.A., Butler, J.E., and Osborne, J.W. 1980. The binding characteristics of proteins for polystyrene and their significance in solid-phase immunoassays. Anal. Biochem. 105: 375382.[CrossRef][Medline]
Carlson, G.A., Kingsbury, D.T., Goodman, P.A., Coleman, S., Marshall, S.T., DeArmond, S., Westaway, D., and Prusiner, S.B. 1986. Linkage of prion protein and scrapie incubation time genes. Cell 46: 503511.[CrossRef][Medline]
Caughey, B. and Chesebro, B. 1997. Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol. 7: 5662.
Caughey, B.W., Dong, A., Bhat, K.S., Ernst, D., Hayes, S.F., and Caughey, W.S. 1991. Secondary structure analysis of the scrapie-associated protein PrP 2730 in water by infrared spectroscopy. Biochemistry 30: 76727680.[CrossRef][Medline]
Caughey, B., Raymond, G.J., and Bessen, R.A. 1998. Strain-dependent differences in ß-sheet conformations of abnormal prion protein. J. Biol. Chem. 273: 3223032235.
Chandler, R.L. 1961. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet 1: 13781379.[Medline]
Cohen, F.E. and Prusiner, S.B. 1998. Pathologic conformations of prion proteins. Annu. Rev. Biochem. 67: 793819.[CrossRef][Medline]
Dickinson, A.G., Meikle, V.M.H., and Fraser, H. 1968. Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J. Comp. Pathol. 78: 293299.[CrossRef][Medline]
Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., and Tagliavini, F. 1993. Neurotoxicity of a prion protein fragment. Nature 362: 543546.[CrossRef][Medline]
Foster, J.D., Hope, J., and Fraser, H. 1993. Transmission of bovine spongiform encephalopathy to sheep and goats. Vet. Rec. 133: 339341.[Abstract]
Fraser, H. 1979. Neuropathology of scrapie: The precision of the lesions and their diversity. In Slow transmissible diseases of the nervous system (eds. S.B. Prusiner and W.J. Hadlow), Vol. 1, pp. 387406. Academic Press, New York.
Fraser, H. and Dickinson, A.G. 1968. The sequential development of the brain lesions of scrapie in three strains of mice. J. Comp. Pathol. 78: 301311.[CrossRef][Medline]
Gabizon, R., McKinley, M.P., and Prusiner, S.B. 1987. Purified prion proteins and scrapie infectivity copartition into liposomes. Proc. Natl. Acad. Sci. 84: 40174021.
Gajdusek, D.C. 1988. Transmissible and non-transmissible amyloidoses: Autocatalytic post-translational conversion of host precursor proteins to ß-pleated sheet configurations. J. Neuroimmunol. 20: 95110.[CrossRef][Medline]
Gasset, M., Baldwin, M.A., Lloyd, D., Gabriel, J.-M., Holtzman, D.M., Cohen, F., Fletterick, R., and Prusiner, S.B. 1992. Predicted
-helical regions of the prion protein when synthesized as peptides form amyloid. Proc. Natl. Acad. Sci. 89: 1094010944.
Gasset, M., Baldwin, M.A., Fletterick, R.J., and Prusiner, S.B. 1993. Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc. Natl. Acad. Sci. 90: 15.
Gibbs, C.J., Jr., Safar, J., Sulima, M.P., Bacote, A.E., and San Martin, R.A. 1996. Transmission of sheep and goat strains of scrapie from experimentally infected cattle to hamsters and mice. In Bovine spongiform encephalopathy: The BSE dilemma (ed. C.J. Gibbs, Jr.), pp. 8491. Springer, New York.
Hecker, R., Taraboulos, A., Scott, M., Pan, K.-M., Torchia, M., Jendroska, K., DeArmond, S.J., and Prusiner, S.B. 1992. Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters. Genes Dev. 6: 12131228.
Horiuchi, M., Chabry, J., and Caughey, B. 1999. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J. 18: 31933203.[CrossRef][Medline]
Jarrett, J.T. and Lansbury, P.T., Jr. 1993. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 10551058.[CrossRef][Medline]
Kaneko, K., Zulianello, L., Scott, M., Cooper, C.M., Wallace, A.C., James, T.L., Cohen, F.E., and Prusiner, S.B. 1997. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. 94: 1006910074.
Kascsak, R.J., Rubenstein, R., Merz, P.A., Carp, R.I., Robakis, N.K., Wisniewski, H.M., and Diringer, H. 1986. Immunological comparison of scrapie-associated fibrils isolated from animals infected with four different scrapie strains. J. Virol. 59: 676683.
Kascsak, R.J., Rubenstein, R., Merz, P.A., Tonna-DeMasi, M., Fersko, R., Carp, R.I., Wisniewski, H.M., and Diringer, H. 1987. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J. Virol. 61: 36883693.
Kimberlin, R.H., Walker, C.A., and Fraser, H. 1989. The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J. Gen. Virol. 70: 20172025.
Kitamoto, T., Ogomori, K., Tateishi, J., and Prusiner, S.B. 1987. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab. Invest. 57: 230236.[Medline]
Kuwajima, K. 1995. Circular dichroism. In Methods in molecular biology: Protein stability and folding: Theory and practice (ed. B.A. Shirley), pp. 115135. Humana Press, Totowa, NJ.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T-4. Nature 227: 680685.[CrossRef][Medline]
Marsh, R.F. and Kimberlin, R.H. 1975. Comparison of scrapie and transmissible mink encephalopathy in hamsters. II. Clinical signs, pathology and pathogenesis. J. Infect. Dis. 131: 104110.[Medline]
Mastrianni, J.A., Nixon, R., Layzer, R., Telling, G.C., Han, D., DeArmond, S.J., and Prusiner, S.B. 1999. Prion protein conformation in a patient with sporadic fatal insomnia. N. Engl. J. Med. 340: 16301638.
McKinley, M.P., Meyer, R.K., Kenaga, L., Rahbar, F., Cotter, R., Serban, A., and Prusiner, S.B. 1991. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J. Virol. 65: 13401351.
Monari, L., Chen, S.G., Brown, P., Parchi, P., Petersen, R.B., Mikol, J., Gray, F., Cortelli, P., Montagna, P., Ghetti, B., et al. 1994. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Different prion proteins determined by a DNA polymorphism. Proc. Natl. Acad. Sci. 91: 28392842.
Oesch, B., Jensen, M., Nilsson, P., and Fogh, J. 1994. Properties of the scrapie prion protein: Quantitative analysis of protease resistance. Biochemistry 33: 59265931.[CrossRef][Medline]
Pan, K.-M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R.J., Cohen, F.E., et al. 1993. Conversion of
-helices into ß-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. 90: 1096210966.
Parchi, P., Castellani, R., Capellari, S., Ghetti, B., Young, K., Chen, S.G., Farlow, M., Dickson, D.W., Sima, A.A.F., Trojanowski, J.Q., et al. 1996. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 39: 767778.[CrossRef][Medline]
Pattison, I.H. and Millson, G.C. 1961. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J. Comp. Pathol. 71: 101108.
Peretz, D., Williamson, R.A., Matsunaga, Y., Serban, H., Pinilla, C., Bastidas, R.B., Rozenshteyn, R., James, T.L., Houghten, R.A., Cohen, F.E., et al. 1997. A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. J. Mol. Biol. 273: 614622.[CrossRef][Medline]
Pergami, P., Jaffe, H., and Safar, J. 1996. Semipreparative chromatographic method to purify the normal cellular isoform of the prion protein in nondenatured form. Anal. Biochem. 236: 6373.[CrossRef][Medline]
Prusiner, S.B., Cochran, S.P., Groth, D.F., Downey, D.E., Bowman, K.A., and Martinez, H.M. 1982. Measurement of the scrapie agent using an incubation time interval assay. Ann. Neurol. 11: 353358.[CrossRef][Medline]
Prusiner, S.B., McKinley, M.P., Bowman, K.A., Bolton, D.C., Bendheim, P.E., Groth, D.F., and Glenner, G.G. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35: 349358.[CrossRef][Medline]
Prusiner, S.B., Groth, D.F., Bolton, D.C., Kent, S.B., and Hood, L.E. 1984. Purification and structural studies of a major scrapie prion protein. Cell 38: 127134.[CrossRef][Medline]
Prusiner, S.B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G.A., et al. 1990. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63: 673686.[CrossRef][Medline]
Prusiner, S.B., Groth, D., Serban, A., Stahl, N., and Gabizon, R. 1993. Attempts to restore scrapie prion infectivity after exposure to protein denaturants. Proc. Natl. Acad. Sci. 90: 27932797.
Prusiner, S.B., Scott, M.R., DeArmond, S.J., and Cohen, F.E. 1998. Prion protein biology. Cell 93: 337348.[CrossRef][Medline]
Raeber, A.J., Sailer, A., Hegyi, I., Klein, M.A., Rulike, T., Fischer, M., Brandner, S., Aguzzi, A., and Weissmann, C. 1999. Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc. Natl. Acad. Sci. 96: 39873992.
Rodgers, R.P.C. 1984. Data analysis and quality control of assays: A practical primer. In Practical immunoassay: The state of the art (ed. W.R. Butt), pp. 253308. Marcel Dekker, New York.
Rogers, M., Serban, D., Gyuris, T., Scott, M., Torchia, T., and Prusiner, S.B. 1991. Epitope mapping of the Syrian hamster prion protein utilizing chimeric and mutant genes in a vaccinia virus expression system. J. Immunol. 147: 35683574.[Abstract]
Safar, J., Roller, P.P., Gajdusek, D.C., and Gibbs, C.J.J. 1993. Thermal-stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein Sci. 2: 22062216.[Abstract]
Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F.E., and Prusiner, S.B. 1998. Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4: 11571165.[CrossRef][Medline]
Scott, M.R., Groth, D., Tatzelt, J., Torchia, M., Tremblay, P., DeArmond, S.J., and Prusiner, S.B. 1997. Propagation of prion strains through specific conformers of the prion protein. J. Virol. 71: 90329044.[Abstract]
Serban, D., Taraboulos, A., DeArmond, S.J., and Prusiner, S.B. 1990. Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins. Neurology 40: 110117.
Shirley, B.A. 1995. Protein stability and folding: Theory and practice. Humana Press, Totowa, NJ.
Stahl, N., Baldwin, M.A., Teplow, D.B., Hood, L., Gibson, B.W., Burlingame, A.L., and Prusiner, S.B. 1993. Structural analysis of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 32: 19912002.[CrossRef][Medline]
Taraboulos, A., Jendroska, K., Serban, D., Yang, S.-L., DeArmond, S.J., and Prusiner, S.B. 1992. Regional mapping of prion proteins in brains. Proc. Natl. Acad. Sci. 89: 76207624.
Telling, G.C., Scott, M., Mastrianni, J., Gabizon, R., Torchia, M., Cohen, F.E., DeArmond, S.J., and Prusiner, S.B. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83: 7990.[CrossRef][Medline]
Telling, G.C., Parchi, P., DeArmond, S.J., Cortelli, P., Montagna, P., Gabizon, R., Mastrianni, J., Lugaresi, E., Gambetti, P., and Prusiner, S.B. 1996. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274: 20792082.
Wille, H., Zhang, G.-F., Baldwin, M.A., Cohen, F.E., and Prusiner, S.B. 1996. Separation of scrapie prion infectivity from PrP amyloid polymers. J. Mol. Biol. 259: 608621.[CrossRef][Medline]
Williamson, R.A., Burioni, R., Sanna, P.P., Partridge, L.J., Barbas, C.F., III, and Burton, D.R. 1993. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. 90: 41414145.
Williamson, R.A., Peretz, D., Smorodinsky, N., Bastidas, R., Serban, H., Mehlhorn, I., DeArmond, S.J., Prusiner, S.B., and Burton, D.R. 1996. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc. Natl. Acad. Sci. 93: 72797282.
Williamson, R.A., Peretz, D., Pinilla, C., Ball, H., Bastidas, R.B., Rozenshteyn, R., Houghten, R.A., Prusiner, S.B., and Burton, D.R. 1998. Mapping the prion protein using recombinant antibodies. J. Virol. 72: 94139418.
Zlotnik, I. and Rennie, J.C. 1965. Experimental transmission of mouse passaged scrapie to goats, sheep, rats and hamsters. J. Comp. Pathol. 75: 147157.[CrossRef][Medline]
Zulianello, L., Kaneko, K., Scott, M., Erpel, S., Han, D., Cohen, F.E., and Prusiner, S.B. 2000. Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J. Virol. 74: 43514360.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. M. Thackray, L. Hopkins, J. Spiropoulos, and R. Bujdoso Molecular and Transmission Characteristics of Primary-Passaged Ovine Scrapie Isolates in Conventional and Ovine PrP Transgenic Mice J. Virol., November 15, 2008; 82(22): 11197 - 11207. [Abstract] [Full Text] [PDF] |